Physician profile
Wilmer Valentin
NPI 1174960967
$1,518.64
in general payments reported to CMS, 2019-2025
17 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.73 · 2020: $173 · 2021: $202 · 2022: $108 · 2023: $247 · 2024: $443 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.05 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $193.71 | 2020-2025 | Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $148.43 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $131.87 | 2019-2025 | Breztri, Airsupra |
| Astellas Pharma US INC | $107.49 | 2024 | Veozah |
| Shield Therapeutics INC | $105.09 | 2023-2024 | Accrufer |
| Abbott Laboratories | $70.16 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $62.98 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.96 | 2019 | |
| Eisai INC. | $44.66 | 2021 | |
| Abbvie INC. | $44.00 | 2021-2025 | |
| Antares Pharma, INC. | $43.26 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Smith+Nephew, INC. | $39.32 | 2022-2025 | Renasys Touch |
| Phathom Pharmaceuticals, INC. | $29.50 | 2024-2025 | Voquezna |
| Dexcom, INC. | $19.12 | 2024 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.05 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilmer Valentin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.